Bausch Deals Delayed Glumetza Generics, $10 Billion Suit Says

Bausch Health Cos. was hit with a $10 billion antitrust lawsuit Aug. 29, claiming its subsidiaries conspired with other pharmaceutical companies to delay generic competition for the diabetes drug Glumetza, which drove up its price exponentially.

The proposed class action also targets Assertio Therapeutics Inc., Lupin Ltd., and Bausch subsidiaries Salix Pharmaceuticals Inc. and Santarus Inc. Bausch was previously known as Valeant Pharmaceuticals Inc., and Assertio is the former Depomed Inc.

The suit accuses Assertio, which originally made Glumetza, and Santarus, its marketing partner, of settling their patent lawsuit over Lupin’s proposed generic on terms that delayed competition ...